News releases from Allergan plc
Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations
December 17, 2017
-- Swanton to Join Allergan Executive Leadership Team Following Departure of Rob Stewart, Executive Vice President and Chief Operating Officer --
Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin
December 12, 2017
Allergan plc (NYSE: AGN) today announced that the CoolSculpting® treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in...
Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research
November 29, 2017
Allergan to present award-winning study and six additional presentations at the 11th European Headache Federation Congress
Allergan to Present at the 2017 Citi Global Healthcare Conference
November 22, 2017
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the 2017 Citi Global Healthcare Conference in New York...
Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
November 16, 2017
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and Development Officer, and Armin Szegedi, Allergan's Vice...
New survey reveals impact, need for greater discussion about treatment options for condition affecting 33 million Americans(1) this Bladder Health Awareness Month
Allergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia
November 12, 2017
-- Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks --
Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans
November 08, 2017
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana,...
Allergan to Present at Credit Suisse 26th Annual Healthcare Conference
November 06, 2017
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that William Meury, Allergan's Chief Commercial Officer, will present at the Credit Suisse 26th Annual Healthcare...
Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion
November 01, 2017
-- Q3 2017 GAAP Continuing Operations Loss Per Share of $12.05; Q3 Non-GAAP Performance Net Income Per Share of $4.15 --
Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual Congress
October 31, 2017
-- Additional data from the Phase 3 VENUS II trial evaluated absence of bleeding in two courses of treatment --
Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)
October 30, 2017
Allergan Board of Directors Announces Fourth Quarter 2017 Cash Dividend and Increases Quarterly Cash Dividend for 2018
October 27, 2017
Allergan to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids at the American Society for Reproductive Medicine 73rd Annual Congress
October 23, 2017
Allergan plc (NYSE: AGN) today announced that it has three oral presentations and a poster being presented at the American Society for Reproductive Medicine's 73rd Annual Congress (ASRM 2017) in San...
Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the U.S. District Court for the Eastern District of Texas...
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
October 16, 2017
Allergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of Gastroenterology (WCOG), American College of Gastroenterology (ACG),...
Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc.
October 12, 2017
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that the Company has reached an agreement with InnoPharma Inc. resolving patent litigation...
Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference
October 11, 2017
Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical Dermatology Conference (FCDC) in Las Vegas from October 12-15....
Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
October 10, 2017
Potential First-in-Class, Oral Treatment for a Condition Affecting an Estimated 26 Million U.S. Women(1)
Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago
October 09, 2017
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster presentation at the Annual American Academy of Optometry...
Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago
October 05, 2017
Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017 American Society for Dermatologic Surgery (ASDS) meeting...
Allergan To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017 In San Diego
October 04, 2017
Allergan plc (NYSE: AGN) a leading global pharmaceutical company committed to improving outcomes and meeting critical needs in infectious diseases, will present new data from its anti-infectives...
FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults
October 03, 2017
BOTOX® COSMETIC IS THE ONLY TREATMENT OF ITS KIND APPROVED BY THE FDA FOR FOREHEAD LINES, CROW'S FEET LINES AND GLABELLAR LINES1
FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)
October 02, 2017
- Application Seeks to Expand Label to Include an Indication and Phase 3 Data for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia...
Allergan to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast
October 02, 2017
Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the open of the U.S. Financial Markets.
ACZONE® (dapsone) Gel, 7.5% Recognized With Teen Vogue Acne Award Win
September 26, 2017
Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in people 12 years and older, has received a...
Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company
September 25, 2017
Allergan Board of Directors Authorizes New $2 Billion Share Repurchase Program, Affirms Commitment to Increasing Cash Dividend Annually
September 25, 2017
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia
September 22, 2017
Allergan plc (NYSE: AGN) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for...